The effects of vaporized cannabis on symptoms associated with chronic obstructive pulmonary disease (COPD) are the target of a new clinical trial that stems from a partnership between medical cannabis products company Tilray and the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, Canada.
The company estimates that 45–90% of adults with advanced COPD suffer from chronic and impairing breathlessness related to physical activity despite optimal treatment of their lung disease with bronchodilators or corticosteroids.
The Phase 2 study titled, “CAN BREATHE in COPD Trial,” (NCT03060993), will study the efficacy of medical cannabis on breathlessness and exercise tolerance in people with advanced COPD. One patient group will receive 35 mg of cannabis (tetrahydrocannabinol/cannabidiol) in vaporized form, and another will receive a placebo.
Primary outcomes include changes in the intensity ratings of perceived breathlessness during cycle exercise testing and changes in cycle exercise